Transplantation of intestinal microbiota: therapeutic potential at diseases of digestive organs
Abstract
The aim of review. To analyze accumulated world data on human fecal microbiota transplantation (FMT) at treatment of digestive diseases.
Summary. Review highlights basic problems of fecal microbiota transplantation — i.e. new and, probably, promising trend in treatment of many diseases, where traditional methods do not provide due results. Main results of FMT received by the present time at certain digestive diseases are discussed. At the same time clinical application of FMT is related to the ethical φ-factor and lack of microbiologic studies.
Conclusion. Progress in understanding of clinical value of faecal microbiota will transform concept of pathogenesis and treatment of set of diseases.
About the Authors
E. V. ShraynerRussian Federation
Shrayner Eugeny V — MD, research associate, laboratory of regenerative medicine
630090, Novosibirsk, Akademika Lavrentyeva pr., 8
S. A. Kurilovich
Russian Federation
M. F. Osipenko
Russian Federation
V. V. Vlasov
Russian Federation
References
1. Agito M.D., Atreja A., Rizk M.K. Fecal microbiota transplantation for recurrent C. difficile infection: Ready for prime time? Cleve Clin J Med 2013; 80(2):101-8.
2. Anderson JL Edney R.J., Whelan K. Systematic review faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36:503-16.
3. Aroniadis O.C., Brandt L.J. Fecal microbiota transplantation: past, present and future. Curr Opin Gastroenterol 2013; 29(1):79-84.
4. Bäckhed F., Ding H., Wang T., et al. The gut microbiota as an environmental factor that regulates fat storage. PNAS. 2004;101(44):15718-23.
5. Borody T.J., Brandt L.J., Paramsothy S. Therapeutic fecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014; 30(1):97105.
6. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107(7):1079-87.doi:10.1038/ ajg.2012.60
7. Chassard C., Dapoigny M., Scott K.P., et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome Aliment Pharmacol Ther 2012; 35:828-38.
8. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infec Dis 2011; 53:994-1002.
9. Huebner E.S., Surawicz C.M. Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol (N-Y) 2006; 2:203-8.
10. Ihunnah C., Khoruts A., Fischer M., et al. Fecal microbiota transplantation (FMT) for treatment of Clostridium difficile infection (CDI) in immunocompromised patients. American College of Gastroenterology 2013 Annual Scientific Meeting. San Diego, California, October 11-16, 2013. Program and abstracts. Abstract 10.
11. Kassam Z., Lee C.H., Yuan Y., Hund R.H. Fecal microbiota transplantation for Clostridium difficile infection. Am J Gastroenterol 2013; 108(4):500-8.
12. Ley R.E., Backhed F., Turnbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology. PNAS. 2005; 102(31):11070-5.
13. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422-31.
14. McFarland L.V., Mulligan M.E., Kwok R.Y.Y., Stamm W.E. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989; 320:204-10.
15. Petrof E.O., Gloor G.B., Vanner S.J., Weese S.J., et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut. Microbiome 2013. 1:3 doi:10.1186/2049-2618-1-3
16. Reid G., Younes J.A., Van der Mei H.C., Gloor G.B., Knight R., Busscher H.J. Microbiota restoration: natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011; 9:27-38.
17. Ridaura V.K., Faith J.J., Rey F.E., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013; 341(6150). DOI:10.1126/ science.1241214.
18. Rohlke F., Stollman N. Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther Adv Gastroenterol 2012; 5(6):403-20.
19. Russell G., Kaplan J., Ferraro M.J., Michelow I.C. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Official journal of the Am Acad Pediatr 2010; 126(1):23942.
20. Sartor R.B. Microbial influences ininflammatory bowel diseases. Gastroenterology 2008; 134:577-94.
21. Tilg H., Kaiser A. Gut microbiome, obesity and metabolic dysfunction. J Clin Invest 2011; 121(6):2126-32 doi:10.1172/JCI58109.
22. Turnbaugh P.J., Gordon J.I. The core gut microbiome. energy balance and obesity. J Physiol 2009; 587(pt 17):4153-8.
23. Vindigni S.M., Broussard E.K., Surawicz C.M. Alteration of the intestinal microbiome. Fecal microbiota transplantation and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol 2013; 7(7):615-28.
24. Vrieze A., van Nood E., Holleman F., et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in subjects with metabolic syndrome. Gastroenterology 2012; 143(4):913-6. e7. doi:10.1053/j. gastro.2012.06.031
Review
For citations:
Shrayner E.V., Kurilovich S.A., Osipenko M.F., Vlasov V.V. Transplantation of intestinal microbiota: therapeutic potential at diseases of digestive organs. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014;24(5):63-68.
Email this article 
